1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation

Competing Bidder For GNC Argues Expected Sale To Chinese Firm Would Cause Security Risks In US

 
• By Malcolm Spicer

DynamicVetnures also contends Harbin Pharmaceutical is attempting to avoid a regulatory review by federal agencies on national security and other questions that is required when foreign companies make large investments in US businesses.

The Great Wall of China on the background and chinese red flag - Image

A private equity group planning to bid for GNC Holdings Inc. in a bankruptcy auction argues that a sale to a Chinese firm that is the largest shareholder and is positioned to acquire full ownership would cause security risks for the US and for consumers.

DynamicVentures LLC also contends in a document detailing its argument against Harbin Pharmaceutical Group Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Wellness

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

NAD Asks FTC To Pull Bandage Off Firm’s Plan To Exhaust Inventory Using ‘2X Faster Healing’ Claim

 
• By Malcolm Spicer

After National Advertising Division attorneys, in a review prompted by a challenge by Band-Aid line marketer Kenvue, recommended ASO LLV cease use of its “up to 2x faster healing” claim, they determined the firm had not fully complied.